APTITUDE HEALTH®

EPICS

EPICS CONGRESS COVERAGE: EHA 2020 – FOCUS ON NHL/CLL

June 2020

BACKGROUND

EPICS

- On June 3, 2020, Aptitude Health brought together a group of scientists and clinical investigators with expertise in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) to attend an expert panel
- The goal of the expert panel was to discuss the latest therapeutic developments and translational research in NHL and CLL treatment, apply these advances to dynamic and oftentimes individualized clinical decision-making, and explore how emerging data will affect ongoing research, development of new compounds, and future treatment paradigms

EXPERT FACULTY

EPICS

CO-CHAIR

Franck Morschhauser, MD, PhD
Centre Hospitalier Universitaire de Lille
Lille, France

CO-CHAIR

Thomas Witzig, MD
Mayo Clinic
Rochester, MN

FACULTY

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Barbara Eichhorst, MD
University of Munich
Munich, Germany

Raul Cordoba, MD, PhD
Fundacion Jimenez Diaz University Hospital
Madrid, Spain

Mathias Rummel, MD, PhD
Justus-Liebig University-Hospital
Giessen, Germany

Pier Luigi Zinzani, MD, PhD
University of Bologna
Bologna, Italy

AGENDA

EPICS

Time (CEST/CDT)	Topic	Speaker/Moderator
15.30 / 8.30 AM (5 min)	**Welcome and Introductions**	Franck Morschhauser, MD, PhD, Thomas Witzig, MD
15.35 / 8.35 AM (10 min)	**Update on DLBCL**	Thomas Witzig, MD
15.45 / 8.45 AM (20 min)	Discussion	Franck Morschhauser, MD, PhD
16.05 / 9.05 AM (5 min)	Key Takeaways	Thomas Witzig, MD
16.10 / 9.10 AM (10 min)	**Update on FL and MCL**	Franck Morschhauser, MD, PhD
16.20 / 9.20 AM (20 min)	Discussion	Thomas Witzig, MD
16.40 / 9.40 AM (5 min)	Key Takeaways	Franck Morschhauser, MD, PhD
16.45 / 9.45 AM (10 min)	**Update on T-Cell Lymphoma**	Raul Cordoba, MD, PhD
16.55 / 9.55 AM (20 min)	Discussion	Thomas Witzig, MD
17.15 / 10.15 AM (5 min)	Key Takeaways	Raul Cordoba, MD, PhD
17.20 / 10.20 AM (10 min)	**Update on CLL**	Barbara Eichhorst, MD
17.30 / 10.30 AM (20 min)	Discussion	Franck Morschhauser, MD, PhD
17.50 / 10.50 AM (5 min)	Key Takeaways	Barbara Eichhorst, MD
17.55 / 10.55 AM (5 min)	**Summary and Closing Remarks**	Franck Morschhauser, MD, PhD, Thomas Witzig, MD

QUOTES (1/2)

EPICS

"[DLBCL] Duration of response is always important, because you can have

QUOTES (2/2)

EPICS

"[CLL] I think now with the new technologies, we really should try to get rid

APTITUDE HEALTH®

EPICS

Update on DLBCL

THOMAS WITZIG, MD

S232: INOTUZUMAB OZOGAMICIN PLUS R-CVP IS A FEASIBLE AND EFFECTIVE REGIMEN FOR FRONTLINE TREATMENT OF DLBCL IN PATIENTS WHO ARE UNFIT FOR R-CHOP: RESULTS OF A RANDOMISED PHASE 2 UK NCRI TRIAL. FIRST AUTHOR: ELIZABETH PHILLIPS

EPICS

Background

- In a phase II trial, inotuzumab ozogamicin (InO) plus rituximab, cyclophosphamide, vincristine, prednisone (R-

S233: INITIAL RESULTS OF A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. FIRST AUTHOR: CARMELO CARLO-STELLA

EPICS

Background

- A phase II trial with single-agent loncastuximab tesirine (Lonca) in patients with relapsed DLBCL. Lonca is a

EP1284: INTERIM RESULTS OF A PHASE 1/2 STUDY OF LONCASTUXIMAB TESIRINE (LONCA) COMBINED WITH IBRUTINIB IN ADVANCED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OR MANTLE CELL LYMPHOMA (MCL). FIRST AUTHOR: JULIEN DEPAUS

EPICS

Background

> A phase I/II trial with Lonca combined with ibrutinib in

S234: EFFICACY AND SAFETY OF ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAS: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA. FIRST AUTHOR: CHARLES HERBAUX

EPICS

Background

- A phase II trial with the addition of atezolizumab to obinutuzumab and venetoclax in relapsed or refractory

S238: RE-MIND STUDY: COMPARISON OF TAFASITAMAB + LENALIDOMIDE (L-MIND) VS LENALIDOMIDE MONOTHERAPY (REAL-WORLD DATA) IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. FIRST AUTHOR: PIER LUIGI ZINZANI

EPICS

Background

- A phase II trial with tafasitamab in combination with lenalidomide in R/R DLBCL

EP1201: LONG-TERM OUTCOMES FROM THE PHASE II L-MIND STUDY OF TAFASITAMAB (MOR208) PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. FIRST AUTHOR: GILLES SALLES

EPICS

Background

- An update of the L-MIND study with long-term clinical efficacy of tafasitamab plus lenalidomide in R/R DLBCL

SADAL STUDY (1/2)

EPICS

- **EP1226:** EFFICACY AND SAFETY OF SINGLE AGENT ORAL SELINEXOR IN PATIENTS WITH

SADAL STUDY (2/2)

EPICS

DISCUSSION ON DLBCL: CLASSIFICATION

EPICS

- The role of cell of origin is dynamically changing in DLBCL, and a new molecular classification for

DISCUSSION ON DLBCL: FRONTLINE

EPICS

- The treatment of frail patients with DLBCL is an unmet need, as they cannot tolerate intensive

DISCUSSION ON DLBCL: RELAPSED/REFRACTORY (1/2)

EPICS

- The typical benchmarks of a novel drug for R/R DLBCL are

DISCUSSION ON DLBCL: RELAPSED/REFRACTORY (2/2)

EPICS

- The combination of atezolizumab with obinutuzumab and venetoclax in R/R DLBCL showed

DISCUSSION ON DLBCL: NOVEL THERAPIES

EPICS

- Immune checkpoint inhibitors combined with chemotherapies have a strong rationale; however,

APTITUDE HEALTH®

EPICS

Update on FL and MCL

FRANCK MORSCHHAUSER, MD, PHD

MCL ABSTRACTS – S228: IBRUTINIB, VENETOCLAX PLUS OBINUTUZUMAB IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS. FIRST AUTHOR: STEVEN LE GOUILL

EPICS

MCL ABSTRACTS – S229: IBRUTINIB COMPARED TO IMMUNO-CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RELAPSE OF MANTLE CELL LYMPHOMA: A REPORT FROM FONDAZIONE ITALIANA LINFOMI (FIL) AND EUROPEAN MANTLE CELL LYMPHOMA NETWORK (EMCLN). FIRST AUTHOR: CHIARA RUSCONI

EPICS

MCL ABSTRACTS – EP1177: IBRUTINIB AS SECOND-LINE THERAPY IS WELL TOLERATED AND EFFICACIOUS IN FRAIL PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA WHO ARE UNSUITABLE FOR STANDARD FRONT-LINE THERAPIES. FIRST AUTHOR: SOPHIE JOHNS

EPICS

FL ABSTRACTS – GALLIUM STUDY (1/2)

EPICS

> **EP1170:** SUSTAINED CLINICAL BENEFIT OF OBINUTUZUMAB PLUS CHEMOTHERAPY

FL ABSTRACTS – GALLIUM STUDY (2/2)

EPICS

FL ABSTRACTS – EP1161: MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA. FIRST AUTHOR: MATHIAS J. RUMMEL

EPICS

FL ABSTRACTS – EP1162: POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + VENETOCLAX (VEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL. FIRST AUTHOR: SAM YUEN

EPICS

DISCUSSION ON MCL: FIRST LINE (1/2)

- The first-line treatment decision in MCL became very complex with the addition of novel chemo-free regimens

DISCUSSION ON MCL: FIRST LINE (2/2)

EPICS

- Some MCL patients have high blast count in their bone marrow at diagnosis. These patients

DISCUSSION ON MCL: MRD MONITORING

EPICS

- MRD monitoring is part of MCL clinical trials, but not routinely used in clinical practice. At present,

DISCUSSION ON MCL: RELAPSED/REFRACTORY

EPICS

- CNS relapse is becoming more prominent in MCL with the extension of patients' life span and the fact

DISCUSSION ON FL: FIRST LINE

EPICS

- PET is a prognostic tool in FL and patients are monitored after induction therapy; however, it is very difficult to

DISCUSSION ON FL: RELAPSED/REFRACTORY

- There is a level of consensus in the R/R setting for the use of lenalidomide with rituximab in FL

APTITUDE HEALTH®

EPICS

Update on T-Cell Lymphoma

RAUL CORDOBA, MD, PHD

CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF PERIPHERAL T-CELL LYMPHOMAS IN A SPANISH POPULATION: A RETROSPECTIVE STUDY. RODRIGUEZ-PINILLA SM, ET AL. BR J HAEMATOL. 2020 MAY 19. DOI: 10.1111/BJH.16741. ONLINE AHEAD OF PRINT.

EPICS

EP1204: PROOF OF CONCEPT FOR TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY. FIRST AUTHOR: THOMAS WITZIG

EPICS

EP1216: COMBINATION TREATMENT WITH COPANLISIB, A PI3K INHIBITOR, AND GEMCITABINE IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS (RR-PTCL); A MULTICENTER, OPEN-LABEL, PHASE 1/2 TRIAL (COSMOS TRIAL). FIRST AUTHOR: HO-YOUNG YHIM

EPICS

EP1235: TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMAS: SAFETY AND EFFICACY RESULTS FROM A PHASE 2 STUDY. FIRST AUTHOR: PIER LUIGI ZINZANI

EPICS

EP1266: CORRELATION OF PD-L1 EXPRESSION WITH RESPONSE - PHASE I/II TRIAL OF PEMBROLIZUMAB AND ROMIDEPSIN IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA. FIRST AUTHOR: MELODY BECNEL

EPICS

EP1274: COMBINATION OF BRENTUXIMAB-VEDOTIN AND IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE (ICE) IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA. FIRST AUTHOR: ZOE VAN DE WYNGAERT

EPICS

DISCUSSION ON TCL: FIRST LINE

EPICS

- TCL represents a group of diseases with very poor prognosis compared with B-cell lymphomas.

DISCUSSION ON TCL: RELAPSED/REFRACTORY

EPICS

- In the R/R setting of TCL there are multiple signaling pathways under clinical investigation

DISCUSSION ON TCL: RELAPSED/REFRACTORY (1/2)

PI3K inhibitors

DISCUSSION ON TCL: RELAPSED/REFRACTORY (2/2)

Immune checkpoint inhibitors

APTITUDE HEALTH®

EPICS

Update on CLL

BARBARA EICHHORST, MD

S155: FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL. FIRST AUTHOR: OTHMAN AL-SAWAF

EPICS

S157: CLL2-GIVE, A PROSPECTIVE, OPEN-LABEL, MULTICENTER PHASE-II TRIAL OF OBINUTUZUMAB (GA101, G), IBRUTINIB (I), PLUS VENETOCLAX (VE) IN UNTREATED PATIENTS WITH CLL WITH 17P DELETION / TP53 MUTATION. FIRST AUTHOR: HENRIETTE HUBER

EPICS

S158: FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT. FIRST AUTHOR: TANYA SIDDIQI

EPICS

S162: INITIAL RESULTS OF A MULTICENTER, INVESTIGATOR-INITIATED STUDY OF MRD DRIVEN TIME LIMITED THERAPY WITH ZANUBRUTINIB, OBINUTUZUMAB AND VENETOCLAX. FIRST AUTHOR: JACOB SOUMERAI

EPICS

S159: ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ASCEND FINAL RESULTS. FIRST AUTHOR: PAOLO GHIA

EPICS

DISCUSSION ON CLL: FIXED VS CONTINUOUS TREATMENT

EPICS

- Fixed-duration treatment with ibrutinib or novel treatment combinations such as chemotherapy plus

DISCUSSION ON CLL: TREATMENT SEQUENCING (1/2)

EPICS

- There is a need for clarity on treatment sequencing between ibrutinib and venetoclax in CLL. PFS2 in

DISCUSSION ON CLL: TREATMENT SEQUENCING (2/2)

EPICS

- Outside clinical trials it is not yet recommended to rechallenge patients from first-line therapy; there

DISCUSSION ON CLL: TREATMENT COMBINATIONS

EPICS

- There are some patients with very long durable responses to venetoclax combinations for whom

DISCUSSION ON CLL: BTK INHIBITORS

EPICS

- There are multiple BTK inhibitors used in clinical practice and in clinical trials as monotherapy or

DISCUSSION ON CLL: MOLECULAR TESTING

EPICS

- MRD testing is used only in some research centers outside clinical trials. This is not standard